Mim Daroo Company Medicine, Saliravira, To Reduce COVID19 Effects, Was Granted A Global Patent

With the efforts made by the researchers in Mim Daroo Company, a member of Pardis Technology Park, Saliravira, the drug to reduce the effects of COVID19 received a global patent.

The Chief Executive Officer of Mim Daroo Reza Ramezani said that the company signed a contract with a reputable company in Europe to defend it legally.

Since the technical part of the patent is a very tedious and specialized work, we needed an experienced company to help us, he added.

Due to the fact that Iran does not have much experience in the field of global patents in the pharmaceutical sector, a very extensive systematic work was done, he stated.

We were aimed at cooperating with large companies in the production and distribution of medicines at the global level, he said.

Last year and at the same time as one of the biggest COVID19 peaks in Iran, with the scientific efforts of more than 40 researchers from the top Iranian universities, Salivira as the first COVID19 domestic drug in Mim Daroo knowledge-based company a member of Pardis Technology Park was produced.